Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial
27.10.2025 16:03
The gene-editing biotech Intellia Therapeutics said Monday it had paused two trials of one of its lead experimental treatments after a patient was hospitalized due to liver problems. On an investor call, Intellia’s CEO, John Leonard, said that the company had learned Friday that a patient in a trial of the company’s experimental gene-editing treatment for a heart disease called ATTR-cardiomyopathy had been hospitalized after reporting stomach pain.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
27.10.2025 14:00
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
27.10.2025 13:00
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
08.10.2025 13:00
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Smartest Growth Stock to Buy With $500 Right Now
08.10.2025 08:42
Vertex isn't your run-of-the-mill biotech stock.
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?
08.10.2025 04:03
Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital, which is disappointing considering the S&P 500 has climbed by 34.7%. This might have investors contemplating their next move.
Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?
26.09.2025 13:30
Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript
23.09.2025 07:53
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bank of America Global Healthcare Conference 2025 September 23, 2025 3:10 AM EDTCompany ParticipantsSusie...
Vertex Plunges Around 24% in Six Months: How to Play the Stock
17.09.2025 14:28
Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.
How Recent FDA Approval Impacts the Valuation Story for Vertex Pharmaceuticals in 2025
17.09.2025 12:41
If you have been eyeing Vertex Pharmaceuticals and wondering whether it is the right time to buy, sell, or simply hold tight, you are far from alone. Vertex has been on a journey, sometimes up, sometimes down, which has kept investors on their toes. Over the past year, the stock fell 18.7%, a move that might make some skittish, while longer-term holders can still point to impressive gains of 36.4% over three years and 46.3% over five. Shorter-term numbers, like the -1.3% seven-day return and...
Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality
13.09.2025 08:19
Vertex Pharmaceuticals is backed by CF dominance and JOURNAVX optionality, with key catalysts ahead for growth and upside. See why VRTX stock is a buy.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
12.09.2025 14:00
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
09.09.2025 14:01
Get insights from Vertex Pharmaceuticals at the Morgan Stanley Global Healthcare
Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy
02.09.2025 09:37
Satellos has the potential to produce substantial rewards if SAT-3247 can demonstrate sufficient muscle regeneration in DMD patients in a safe and tolerable manner
BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH
01.09.2025 08:03
Biotech is entering a new growth cycle driven by AI and CRISPR innovation, but current ETF valuations are high and volatility is elevated.
National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry
27.08.2025 15:31
Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs’ National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division’s (NAD) inquiry.New York, NY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs’ Nat
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
27.08.2025 13:00
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Do Wall Street Analysts Like Vertex Pharmaceuticals Stock?
25.08.2025 06:57
Vertex Pharmaceuticals has significantly underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects.
Hartford Healthcare Fund Q2 2025 Commentary
21.08.2025 10:25
The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.
Goldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged
19.08.2025 03:15
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 11, Goldman Sachs analyst Salveen Richter reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a price target of $624. The reiterated bullish sentiment follows the announcement of strong fiscal second-quarter results by the […]